[
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’",
    "summary": "We recently compiled a list of the Jim Cramer’s Lightning Round: 8 Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Jim Cramer’s other stocks. Jim Cramer, the host of Mad Money, recently shared his insights on several key topics. He discussed the […]",
    "url": "https://finnhub.io/api/news?id=7280803814c001a0888985ac7c0842e9e61a71f084a13e30035bdb30e63eddcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732143862,
      "headline": "Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’",
      "id": 131522618,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Jim Cramer’s Lightning Round: 8 Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Jim Cramer’s other stocks. Jim Cramer, the host of Mad Money, recently shared his insights on several key topics. He discussed the […]",
      "url": "https://finnhub.io/api/news?id=7280803814c001a0888985ac7c0842e9e61a71f084a13e30035bdb30e63eddcf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=826d32d301ae3f52e9551f85d950b37071f217555659e4e1f6582a0336825faa",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732120380,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 131528346,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=826d32d301ae3f52e9551f85d950b37071f217555659e4e1f6582a0336825faa"
    }
  },
  {
    "ts": null,
    "headline": "Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound",
    "summary": "Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.",
    "url": "https://finnhub.io/api/news?id=f8c40c77bf4b46aca83d6ab51e28c2b39d63256aa5966552ef0ccb4e37bfbb26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732119240,
      "headline": "Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound",
      "id": 131518561,
      "image": "https://media.zenfs.com/en/quartz.com/d28807b7fc9ab26160b80e13e8040cbc",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.",
      "url": "https://finnhub.io/api/news?id=f8c40c77bf4b46aca83d6ab51e28c2b39d63256aa5966552ef0ccb4e37bfbb26"
    }
  },
  {
    "ts": null,
    "headline": "China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug",
    "summary": "Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion in revenue by the next decade.  Last year, the company spent about $2 billion to acquire Versanis' drug that acts directly on fat cells, without prompting lean mass loss.  Several other drugmakers including Regeneron and Scholar Rock are testing treatments that could help preserve muscle, which is often lost when patients lose weight through lifestyle changes, bariatric surgery or the use of GLP-1 treatments such as Lilly's Zepbound and Novo Nordisk's Wegovy.",
    "url": "https://finnhub.io/api/news?id=b1c9386e7d2292996f865e2dcfa64875d75af2c3281273044550f4f83741d7be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732115459,
      "headline": "China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug",
      "id": 131503889,
      "image": "https://media.zenfs.com/en/reuters-finance.com/96d9e7fd2c34dbb2d55d85b941043eac",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion in revenue by the next decade.  Last year, the company spent about $2 billion to acquire Versanis' drug that acts directly on fat cells, without prompting lean mass loss.  Several other drugmakers including Regeneron and Scholar Rock are testing treatments that could help preserve muscle, which is often lost when patients lose weight through lifestyle changes, bariatric surgery or the use of GLP-1 treatments such as Lilly's Zepbound and Novo Nordisk's Wegovy.",
      "url": "https://finnhub.io/api/news?id=b1c9386e7d2292996f865e2dcfa64875d75af2c3281273044550f4f83741d7be"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk",
    "summary": "A short strangle on Eli Lilly will generate $1,125 in option premium and takes advantage of the current high level of implied volatility.",
    "url": "https://finnhub.io/api/news?id=562ed6c786704b92848d9518a96caf5b4c5516a850e626998bb46f59671dd634",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732109057,
      "headline": "Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk",
      "id": 131503890,
      "image": "https://media.zenfs.com/en/ibd.com/75c01687f70f63c85d8c90296f5e1bd1",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A short strangle on Eli Lilly will generate $1,125 in option premium and takes advantage of the current high level of implied volatility.",
      "url": "https://finnhub.io/api/news?id=562ed6c786704b92848d9518a96caf5b4c5516a850e626998bb46f59671dd634"
    }
  },
  {
    "ts": null,
    "headline": "Lilly announces changes on board of directors",
    "summary": "INDIANAPOLIS - Eli Lilly and Company announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024.In addition, the company announced that Karen...",
    "url": "https://finnhub.io/api/news?id=8cc0ba98814209ea49ce222e8c40967b3dae962cecb02347f58eb75ef0cc0707",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732100908,
      "headline": "Lilly announces changes on board of directors",
      "id": 131504348,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024.In addition, the company announced that Karen...",
      "url": "https://finnhub.io/api/news?id=8cc0ba98814209ea49ce222e8c40967b3dae962cecb02347f58eb75ef0cc0707"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time to Sell Eli Lilly and Pfizer Stocks?",
    "summary": "Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE).  When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine.  Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid.",
    "url": "https://finnhub.io/api/news?id=97d714c48be52e75f078cb155518df6c8e046987873567520b6e6ef4c201c5ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732099680,
      "headline": "Is It Time to Sell Eli Lilly and Pfizer Stocks?",
      "id": 131499488,
      "image": "https://g.foolcdn.com/editorial/images/798328/scientist-with-head-down.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE).  When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine.  Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid.",
      "url": "https://finnhub.io/api/news?id=97d714c48be52e75f078cb155518df6c8e046987873567520b6e6ef4c201c5ca"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley",
    "summary": "Eli Lilly, PepsiCo and Morgan Stanley are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=a11e8d84df504c1c44724df25dce5832e9792d6c826be4ad371936b92e7d1813",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732096800,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley",
      "id": 131500189,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, PepsiCo and Morgan Stanley are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=a11e8d84df504c1c44724df25dce5832e9792d6c826be4ad371936b92e7d1813"
    }
  },
  {
    "ts": null,
    "headline": "Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS",
    "summary": "— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transfo",
    "url": "https://finnhub.io/api/news?id=13f665af5a17666f7ebfe48b2024e6210faa8bab8d31098759dd624e2c5ddbbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732096800,
      "headline": "Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS",
      "id": 131499490,
      "image": "https://s.yimg.com/ny/api/res/1.2/q64jmzGAzW7NwFlhfAdRyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/globenewswire.com/f1da1d126a653bdd5c31f049f8f127b3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transfo",
      "url": "https://finnhub.io/api/news?id=13f665af5a17666f7ebfe48b2024e6210faa8bab8d31098759dd624e2c5ddbbf"
    }
  },
  {
    "ts": null,
    "headline": "XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)",
    "summary": "We advise selling healthcare stocks due to political uncertainty and unfavorable market conditions, prioritizing low-risk investments. See more on XLV ETF here.",
    "url": "https://finnhub.io/api/news?id=fda1041225add2352abc51ab2126c9563bd38831235bdf55044cf40be42ddef3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732093680,
      "headline": "XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)",
      "id": 131502070,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1496411389/image_1496411389.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "We advise selling healthcare stocks due to political uncertainty and unfavorable market conditions, prioritizing low-risk investments. See more on XLV ETF here.",
      "url": "https://finnhub.io/api/news?id=fda1041225add2352abc51ab2126c9563bd38831235bdf55044cf40be42ddef3"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Advantage Large Cap Core V.I. Fund Q3 2024 Commentary",
    "summary": "BlackRock Advantage Large Cap Core V.I. Fund posted a return of 5.78% (Class I shares) for the third quarter of 2024. Read more here.",
    "url": "https://finnhub.io/api/news?id=2d2813f84aa95983920203a29d178936fe34427b5fd2720474609eaa7480a05a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732091820,
      "headline": "BlackRock Advantage Large Cap Core V.I. Fund Q3 2024 Commentary",
      "id": 131501627,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072594058/image_1072594058.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Advantage Large Cap Core V.I. Fund posted a return of 5.78% (Class I shares) for the third quarter of 2024. Read more here.",
      "url": "https://finnhub.io/api/news?id=2d2813f84aa95983920203a29d178936fe34427b5fd2720474609eaa7480a05a"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.",
    "summary": "Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health and Human Services.",
    "url": "https://finnhub.io/api/news?id=970a54c5765fa96e24beb7a783353e8e1334b142029656baaa145792c3f24e92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732091400,
      "headline": "RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.",
      "id": 131497213,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health and Human Services.",
      "url": "https://finnhub.io/api/news?id=970a54c5765fa96e24beb7a783353e8e1334b142029656baaa145792c3f24e92"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Advantage Large Cap Core Fund Q3 2024 Commentary",
    "summary": "BlackRock Advantage Large Cap Core Fund posted returns of 6.12% (Institutional shares) and 6.01% (Investor A shares, without sales charge) for the third quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=c3ef4f53d3c18eb789dbb89d5d1c2cf7de8c5632ea8ac98fc9ff73740e20f119",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732085160,
      "headline": "BlackRock Advantage Large Cap Core Fund Q3 2024 Commentary",
      "id": 131499235,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305707642/image_1305707642.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Advantage Large Cap Core Fund posted returns of 6.12% (Institutional shares) and 6.01% (Investor A shares, without sales charge) for the third quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=c3ef4f53d3c18eb789dbb89d5d1c2cf7de8c5632ea8ac98fc9ff73740e20f119"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Sustainable Advantage Large Cap Core Fund Q3 2024 Commentary",
    "summary": "BlackRock Sustainable Advantage Large CapÂ Core Fund  posted returns of 5.20% (I) for the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=a412c3dda17e5a8868ec673a2bdd97d846b77fd6557082b0f61022b675a53545",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732083600,
      "headline": "BlackRock Sustainable Advantage Large Cap Core Fund Q3 2024 Commentary",
      "id": 131498900,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1605541393/image_1605541393.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Sustainable Advantage Large CapÂ Core Fund  posted returns of 5.20% (I) for the third quarter of 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=a412c3dda17e5a8868ec673a2bdd97d846b77fd6557082b0f61022b675a53545"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss drug coverage rises among largest US employers, Mercer survey finds",
    "summary": "About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday. ...",
    "url": "https://finnhub.io/api/news?id=27b1259c24e0519c1d206002253b32b2cd5f745690e938757035847e1d7f839b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732083320,
      "headline": "Weight-loss drug coverage rises among largest US employers, Mercer survey finds",
      "id": 131498814,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday. ...",
      "url": "https://finnhub.io/api/news?id=27b1259c24e0519c1d206002253b32b2cd5f745690e938757035847e1d7f839b"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Advantage Large Cap Growth Fund Q3 2024 Commentary",
    "summary": "The fund posted returns of 3.83% (Institutional shares) and 3.79% (Investor A shares, without sales charge) for the third quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=25d4b06ea813e4789b73610e77c729d7b63294553875836a4d558124c18052ba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732082700,
      "headline": "BlackRock Advantage Large Cap Growth Fund Q3 2024 Commentary",
      "id": 131498745,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/139704724/image_139704724.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The fund posted returns of 3.83% (Institutional shares) and 3.79% (Investor A shares, without sales charge) for the third quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=25d4b06ea813e4789b73610e77c729d7b63294553875836a4d558124c18052ba"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Capital Appreciation Fund Q3 2024 Commentary",
    "summary": "The BlackRock Capital Appreciation Fund posted returns of 1.38% (I) for the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=d5ce8e71c96c11515c38dce9f75d36eb3d0385dd0bee1c99fda91c3236b98033",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732079400,
      "headline": "BlackRock Capital Appreciation Fund Q3 2024 Commentary",
      "id": 131498117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250451822/image_1250451822.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The BlackRock Capital Appreciation Fund posted returns of 1.38% (I) for the third quarter of 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=d5ce8e71c96c11515c38dce9f75d36eb3d0385dd0bee1c99fda91c3236b98033"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Procter & Gamble CEO joins board",
    "summary": "Eli Lilly announced yesterday the election of Jon Moeller, Chairman and CEO of Procter & Gamble, as a new member of its Board of Directors, effective December 1, 2024. He will sit on the Audit and...",
    "url": "https://finnhub.io/api/news?id=db474fb168ce2af8ad6624f321c6d828ef0b6b5a04aaf0b8572052fc7a780e27",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732075214,
      "headline": "Eli Lilly: Procter & Gamble CEO joins board",
      "id": 131497082,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announced yesterday the election of Jon Moeller, Chairman and CEO of Procter & Gamble, as a new member of its Board of Directors, effective December 1, 2024. He will sit on the Audit and...",
      "url": "https://finnhub.io/api/news?id=db474fb168ce2af8ad6624f321c6d828ef0b6b5a04aaf0b8572052fc7a780e27"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Capital Appreciation V.I. Fund Q3 2024 Commentary",
    "summary": "BlackRock Capital Appreciation V.I. Fund posted a return of 1.19% (Class I shares) for the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=dea6ff73645c15442ba8748241fb19e180adb0dcc53db86da32a908533ac3a0d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732074900,
      "headline": "BlackRock Capital Appreciation V.I. Fund Q3 2024 Commentary",
      "id": 131497035,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/506351198/image_506351198.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Capital Appreciation V.I. Fund posted a return of 1.19% (Class I shares) for the third quarter of 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=dea6ff73645c15442ba8748241fb19e180adb0dcc53db86da32a908533ac3a0d"
    }
  }
]